JP6231548B2 - カテプシンの阻害のための組成物および方法 - Google Patents

カテプシンの阻害のための組成物および方法 Download PDF

Info

Publication number
JP6231548B2
JP6231548B2 JP2015501691A JP2015501691A JP6231548B2 JP 6231548 B2 JP6231548 B2 JP 6231548B2 JP 2015501691 A JP2015501691 A JP 2015501691A JP 2015501691 A JP2015501691 A JP 2015501691A JP 6231548 B2 JP6231548 B2 JP 6231548B2
Authority
JP
Japan
Prior art keywords
cathepsin
compound
composition
mmol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015501691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521156A5 (OSRAM
JP2015521156A (ja
Inventor
デイビッド ジェイ． チャップリン，
デイビッド ジェイ． チャップリン，
デバンナ， クマール キショア ガダル
デバンナ， クマール キショア ガダル
エリカ パーカー，
エリカ パーカー，
ピニー，　ケビン　ジー．
ケビン ジー． ピニー，
ジアンリ ソン，
ジアンリ ソン，
マリー エル． トラウィック，
マリー エル． トラウィック，
Original Assignee
マテオン セラピューティクス， インコーポレイテッド
マテオン セラピューティクス， インコーポレイテッド
ベイラー ユニバーシティ
ベイラー ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マテオン セラピューティクス， インコーポレイテッド, マテオン セラピューティクス， インコーポレイテッド, ベイラー ユニバーシティ, ベイラー ユニバーシティ filed Critical マテオン セラピューティクス， インコーポレイテッド
Publication of JP2015521156A publication Critical patent/JP2015521156A/ja
Publication of JP2015521156A5 publication Critical patent/JP2015521156A5/ja
Application granted granted Critical
Publication of JP6231548B2 publication Critical patent/JP6231548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • C07C337/08—Compounds containing any of the groups, e.g. thiosemicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. thiosemicarbazones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/784—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
    • C07C49/786—Benzophenone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015501691A 2012-03-23 2013-03-05 カテプシンの阻害のための組成物および方法 Active JP6231548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615091P 2012-03-23 2012-03-23
US61/615,091 2012-03-23
PCT/US2013/029106 WO2013142038A2 (en) 2012-03-23 2013-03-05 Compositions and methods for inhibition of cathepsins

Publications (3)

Publication Number Publication Date
JP2015521156A JP2015521156A (ja) 2015-07-27
JP2015521156A5 JP2015521156A5 (OSRAM) 2016-04-14
JP6231548B2 true JP6231548B2 (ja) 2017-11-15

Family

ID=49223437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501691A Active JP6231548B2 (ja) 2012-03-23 2013-03-05 カテプシンの阻害のための組成物および方法

Country Status (7)

Country Link
US (3) US8877967B2 (OSRAM)
EP (1) EP2828241B1 (OSRAM)
JP (1) JP6231548B2 (OSRAM)
AU (1) AU2013235729B2 (OSRAM)
CA (1) CA2865504A1 (OSRAM)
NZ (1) NZ629898A (OSRAM)
WO (1) WO2013142038A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11130631B2 (en) 2014-12-12 2021-09-28 : Symbolic LLC Storage and retrieval system

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865504A1 (en) * 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
EP4148047A1 (en) 2016-07-25 2023-03-15 The Boeing Company Epoxy resin
EP3558918B1 (en) * 2016-12-21 2021-11-10 Solvay Specialty Polymers USA, LLC Method for decreasing the concentration of a metal in a monomer composition comprising bis(benzoyl)benzene
US20180198740A1 (en) * 2017-01-06 2018-07-12 David Rademacher System and method for sharing and updating contact information
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
US10487057B1 (en) * 2018-07-05 2019-11-26 Landos Biopharma, Inc. NLRX1 ligands
CN110857267B (zh) * 2018-08-22 2022-12-09 昱镭光电科技股份有限公司 芳香酮化合物及其有机发光器件
US11329823B2 (en) 2019-09-26 2022-05-10 Bank Of America Corporation User authentication using tokens
US11303629B2 (en) 2019-09-26 2022-04-12 Bank Of America Corporation User authentication using tokens

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
CA2058764A1 (en) 1989-04-28 1990-10-29 Peter D. Hodson Dry powder inhalation device
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
PT96059B (pt) 1989-12-04 1998-07-31 Searle & Co Sistema de camada unica para a administracao de um medicamento por via transdermica
US5364833A (en) 1990-05-09 1994-11-15 Basf Aktiengesellschaft Cyclohexenone oxime ethers, their preparation and their use as herbicides
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
US5277195A (en) 1992-02-03 1994-01-11 Dura Pharmaceuticals, Inc. Portable spirometer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
RO113214B1 (ro) 1992-10-19 1998-05-29 Dura Pharma Inc Inhalator de pulbere uscata
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US6131567A (en) 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
JPH08509465A (ja) 1993-01-29 1996-10-08 マイリス メディカル コーポレーション ホルモンの肺内送達
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
WO2001051030A1 (en) 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US6897240B2 (en) 2002-05-08 2005-05-24 The Regents Of The University Of California Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
ZA200607582B (en) 2004-03-05 2009-02-25 Univ California Anti-parasitic compounds and methods of their use
US8173696B2 (en) * 2007-06-13 2012-05-08 Baylor University Inhibitors of cysteine proteases and methods of use thereof
CA2746070C (en) * 2008-12-12 2017-01-10 The University Of Melbourne Process for the preparation of asymmetrical bis(thiosemicarbazones)
CA2865504A1 (en) * 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11130631B2 (en) 2014-12-12 2021-09-28 : Symbolic LLC Storage and retrieval system

Also Published As

Publication number Publication date
CA2865504A1 (en) 2013-09-26
WO2013142038A3 (en) 2015-06-18
EP2828241A2 (en) 2015-01-28
US8877967B2 (en) 2014-11-04
EP2828241A4 (en) 2016-06-29
AU2013235729B2 (en) 2017-06-01
AU2013235729A1 (en) 2014-10-09
US20160368869A1 (en) 2016-12-22
US9458103B2 (en) 2016-10-04
US20150031915A1 (en) 2015-01-29
NZ629898A (en) 2016-04-29
WO2013142038A2 (en) 2013-09-26
JP2015521156A (ja) 2015-07-27
EP2828241B1 (en) 2018-09-12
US20130296605A1 (en) 2013-11-07
US9873668B2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
JP6231548B2 (ja) カテプシンの阻害のための組成物および方法
US20250122194A1 (en) Novel small molecule inhibitors of tead transcription factors
JP5960770B2 (ja) ヒトピルビン酸キナーゼ活性化剤
ES2641478T3 (es) Derivados de 3-acetilamino-1-(fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino)benceno para el tratamiento de trastornos hiperproliferativos
US9365556B2 (en) 3,5-diaminopyrazole kinase inhibitors
EA016674B1 (ru) Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов mek
JP2013545750A (ja) Ｎａｍｐｔ阻害剤
JP7174963B2 (ja) 疾患の処置のための複素環化合物
CN1319088A (zh) 芳基磺酰基苯胺脲酶
JP7374496B2 (ja) Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用
US20240287048A1 (en) Substituted acyl sulfonamides for treating cancer
CN107074856A (zh) CaMKII抑制剂及其用途
JP6382964B2 (ja) フタラジン誘導体
JP2018087173A (ja) 悪性脳腫瘍治療薬
CN108064222A (zh) N-苯基-(吗啉-4-基或哌嗪基)乙酰胺衍生物及其作为wnt信号通路抑制剂的用途
US20190010173A1 (en) Compositions and methods for inhibition of cathepsins
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
JP2016534049A (ja) 内皮リパーゼ阻害を示す官能基化フラン−２−スルホンアミド
JP2005023007A (ja) 複素環化合物およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170815

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171019

R150 Certificate of patent or registration of utility model

Ref document number: 6231548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250